Benidipine in Hypertensive and/or Chronic Coronary Syndrome Patients

NCT06808321 | Enrolling By Invitation

• 1 other identifier: 2025-01
• Study Type: observational
• Target: 800
• Locations: 1 country
• Sites: 1

Brief Summary

Evaluation of the clinical outcomes of Benidipine initiated by physician's preference in patients with hypertension and/or angina pectoris (chronic coronary syndrome) presenting to cardiology outpatient clinics in Turkey.

Conditions

Chronic Coronary Syndrome; Hypertension; Angina Pectoris

Keywords

Coronary artery disease; Hypertension; Angina pectoris

Outcome Measures

Primary Outcomes (2)

• The Percentage of Patients Achieving Target Sitting Blood Pressure of Less Than 130/85

  3 months

• Change in angina symptom severity as measured by the Seattle Angina Questionnaire score from baseline to the end of study

  3 months

Interventions

Benidipine Hydrochloride DRUG

The safety and efficacy of a dihydropyridine calcium channel blocker for the treatment of high blood pressure and/or angina pectoris

Eligibility Criteria

• Age: 18 Years - 80 Years
• Sex: all
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients presenting to cardiology outpatient clinics in Turkey with hypertension and/or angina pectoris (chronic coronary syndrome)

You may qualify if:

• Patients with hypertension and/or angina pectoris on the background of chronic coronary syndrome who have been receiving Benidipine treatment for at least 1 month and will continue to receive Benidipine treatment
• Male or female outpatients, 18-80 years of age
• Patients with mild to moderate essential hypertension who have been receiving or will continue Benidipine treatment for at least 1 month
• Outpatients with clinically stable angina pectoris and patients who have been receiving or will continue Benidipine treatment for at least 1 month
• Those who signed the written informed consent form

You may not qualify if:

• Patients with secondary hypertension
• Emergency hypertensive patients
• Having to take other medications during the study that may affect blood pressure
• Allergic to DHP calcium antagonists
• Evidence of decompensated congestive heart failure, unstable angina or severe arrhythmia
• Severe renal or hepatic dysfunction
• Pregnant or lactating women
• Participation in other clinical trials within 3 months prior to this study
• Patients who did not sign the consent form of the study

Sponsors & Collaborators

• The Society of Prevention and Awareness of Cardiovascular Diseases: lead

Study Sites (1)

Antalya Kepez State Hospital

Antalya, Turkey (Türkiye)

Location

MeSH Terms

Conditions

Hypertension; Angina Pectoris; Coronary Artery Disease

Interventions

benidipine hydrochloride

Condition Hierarchy (Ancestors)

Vascular Diseases; Cardiovascular Diseases; Myocardial Ischemia; Heart Diseases; Chest Pain; Pain; Neurologic Manifestations; Signs and Symptoms; Pathological Conditions, Signs and Symptoms; Coronary Disease; Arteriosclerosis; Arterial Occlusive Diseases

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: CROSS SECTIONAL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: January 26, 2025
• First Posted: February 5, 2025
• Study Start: March 1, 2025
• Primary Completion: January 1, 2026
• Study Completion (Estimated): June 1, 2026
• Last Updated: September 9, 2025

Record last verified: 2025-09

Locations

TU (1)